Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study


Fanouriakis A., Adamichou C., Koutsoviti S., Panopoulos S., Staveri C., Klagou A., ...Daha Fazla

SEMINARS IN ARTHRITIS AND RHEUMATISM, cilt.48, ss.467-474, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 48 Konu: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.semarthrit.2018.02.014
  • Dergi Adı: SEMINARS IN ARTHRITIS AND RHEUMATISM
  • Sayfa Sayıları: ss.467-474

Özet

Background: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.